scholarly journals Alzheimer's Disease Risk Factor Pyk2 Mediates Amyloid-β-Induced Synaptic Dysfunction and Loss

2018 ◽  
Vol 39 (4) ◽  
pp. 758-772 ◽  
Author(s):  
Santiago V. Salazar ◽  
Timothy O. Cox ◽  
Suho Lee ◽  
A. Harrison Brody ◽  
Annabel S. Chyung ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Risk Factor ◽  
Disease Risk ◽  
Amyloid Β ◽  
Synaptic Dysfunction ◽  
Disease Risk Factor

scholarly journals Alzheimer’s disease risk factor mutations in patients diagnosed with Creutzfelt‐Jakob disease

2020 ◽  
Vol 16 (S3) ◽  
Author(s):  
Eva Bagyinszky ◽  
Lindsay A. Farrer ◽  
John Farrell ◽  
Giau Van Vo ◽  
KyuHwan Shim ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Risk Factor ◽  
Disease Risk ◽  
Disease Risk Factor ◽  
Jakob Disease

scholarly journals PICALM Rescues Endocytic Defects Caused by the Alzheimer’s Disease Risk Factor APOE4

Cell Reports ◽  
2020 ◽  
Vol 33 (1) ◽  
pp. 108224
Author(s):  
Priyanka Narayan ◽  
Grzegorz Sienski ◽  
Julia M. Bonner ◽  
Yuan-Ta Lin ◽  
Jinsoo Seo ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Risk Factor ◽  
Disease Risk ◽  
Disease Risk Factor

Alzheimer's disease risk factor complement receptor 1 is associated with depression

2012 ◽  
Vol 510 (1) ◽  
pp. 6-9 ◽  
Author(s):  
Gillian Hamilton ◽  
Kathryn L. Evans ◽  
Donald J. MacIntyre ◽  
Ian J. Deary ◽  
Anna Dominiczak ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Risk Factor ◽  
Disease Risk ◽  
Complement Receptor ◽  
Disease Risk Factor ◽  
Complement Receptor 1

scholarly journals The Alzheimer's disease risk factor CD2AP maintains blood–brain barrier integrity

2015 ◽  
Vol 24 (23) ◽  
pp. 6667-6674 ◽  
Author(s):  
J. Nicholas Cochran ◽  
Travis Rush ◽  
Susan C. Buckingham ◽  
Erik D. Roberson
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Risk Factor ◽  
Blood Brain Barrier ◽  
Disease Risk ◽  
Brain Barrier ◽  
Disease Risk Factor ◽  
Barrier Integrity ◽  
Blood Brain ◽  
Blood Brain Barrier Integrity

scholarly journals P4-517: EXPRESSION OF THE ALZHEIMER'S DISEASE RISK FACTOR SORLA IN THE POSTNATAL MOUSE RETINA

2019 ◽  
Vol 15 ◽  
pp. P1512-P1512
Author(s):  
Giulia Monti ◽  
Marianne Lundsgaard Kristensen ◽  
Arnela Mehmedbasic ◽  
Margarita Melnikova ◽  
Ida E. Holm ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Risk Factor ◽  
Disease Risk ◽  
Mouse Retina ◽  
Disease Risk Factor

P1-087: Placental tau, α-synuclein, Aβ, and app levels in preeclampsia: An Alzheimer's disease risk factor

2015 ◽  
Vol 11 (7S_Part_8) ◽  
pp. P372-P372
Author(s):  
Edward G. Stopa ◽  
James Padbury ◽  
Lori A. Daiello ◽  
Brian R. Ott ◽  
Surendra Sharma
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Risk Factor ◽  
Disease Risk ◽  
Disease Risk Factor

scholarly journals Astrocytes and neuroinflammation in Alzheimer's disease

2014 ◽  
Vol 42 (5) ◽  
pp. 1321-1325 ◽  
Author(s):  
Emma C. Phillips ◽  
Cara L. Croft ◽  
Ksenia Kurbatskaya ◽  
Michael J. O’Neill ◽  
Michael L. Hutton ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Inflammatory Responses ◽  
Amyloid Β ◽  
Synaptic Dysfunction ◽  
Amyloid Β Peptide ◽  
Substantial Evidence ◽  
Models Of Disease ◽  
Opposing Effects

Increased production of amyloid β-peptide (Aβ) and altered processing of tau in Alzheimer's disease (AD) are associated with synaptic dysfunction, neuronal death and cognitive and behavioural deficits. Neuroinflammation is also a prominent feature of AD brain and considerable evidence indicates that inflammatory events play a significant role in modulating the progression of AD. The role of microglia in AD inflammation has long been acknowledged. Substantial evidence now demonstrates that astrocyte-mediated inflammatory responses also influence pathology development, synapse health and neurodegeneration in AD. Several anti-inflammatory therapies targeting astrocytes show significant benefit in models of disease, particularly with respect to tau-associated neurodegeneration. However, the effectiveness of these approaches is complex, since modulating inflammatory pathways often has opposing effects on the development of tau and amyloid pathology, and is dependent on the precise phenotype and activities of astrocytes in different cellular environments. An increased understanding of interactions between astrocytes and neurons under different conditions is required for the development of safe and effective astrocyte-based therapies for AD and related neurodegenerative diseases.

Sign in / Sign up

Export Citation Format

Share Document